DiagnosisGenetics of susceptibility and mortality in critical care (GenOMICC)

Status: Open and recruiting at Royal Brompton Hospital

Type: Observational

Funder: Wellcome Trust

Sponsor: NHS Lothian

CI: Dr Kenneth Baillie

IRAS-Number: 189676

CPMS-ID: 30540

Approval Date: 02 April 2020


Our genes determine how susceptible we are to life-threatening infection. When a patient is already sick, different genetic factors determine how likely they are to survive. The GenOMICC (Genetics of Susceptibility and Mortality in Critical Care) study will identify the specific genes that cause some people to be susceptible to specific infections and consequences of severe injury. Our hope is that identifying these genes will help us to use existing treatments better, and to design new treatments to help people survive critical illness. To do this, we will compare DNA and cells from carefully selected patients with samples from healthy people. Susceptibility to COVID-19 is almost certainly, in part, genetic. GenOMICC can find the genes that cause susceptibility, which may help us to prioritise treatments to respond to the global crisis. GenOMICC was designed for this crisis. Since 2016, the open, global GenOMICC collaboration has been recruiting patients with emerging infections, including COVID-19. All patients with confirmed COVID-19 in critical care are eligible for GenOMICC.

Inclusion criteria:

  • Patients will be recruited who:
    • Are deemed, in the view of the treating physician, to require continuous cardiovascular or respiratory monitoring or invasive mechanical ventilation,
      • AND provide appropriate consent or assent,
      • AND present with one of the following primary diagnoses:
  • Group 1:
    • COVID-19. Confirmed or suspected COVID-19.
    • Influenza. Confirmed infection with influenza virus.
    • Secondary pneumonia. Acute pneumonia complicating confirmed infection with influenza virus.
    • Emerging infections. Confirmed or suspected infection with an emerging infection.
  • Group 2
    • Cellulitis. Soft tissue infections causing systemic sepsis.
    • Burns. Full thickness burns covering 20 − 40% of body surface area.
  • Group 3
    • RSV. Confirmed infection with respiratory syncytial virus.
    • Pneumonia. Primary pneumonia with radiographic changes at presentation to critical care.

Exclusion criteria

  • Non consenting COVID-19 patients